Halozyme Therapeutics, Inc. $HALO Stock: Kornitzer Capital Management Inc. KS Decreases Position

Kornitzer Capital Management Inc. KS decreased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 167,544 shares of the biopharmaceutical company’s stock after selling 18,831 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Halozyme Therapeutics were worth $18,497,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $214,504,000. William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $196,540,000. Jupiter Topco LLC bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $105,570,000. Caisse de depot et placement du Quebec purchased a new position in Halozyme Therapeutics in the second quarter valued at approximately $83,940,000. Finally, Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 85.6% in the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after purchasing an additional 1,052,509 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Key Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock valued at $13,538,046 over the last three months. Company insiders own 2.50% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the subject of several research reports. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Citizens Jmp upped their price target on Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a research report on Friday. TD Cowen increased their price target on Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.09.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $103.63 on Friday. The stock has a market capitalization of $11.76 billion, a P/E ratio of 26.37, a PEG ratio of 0.39 and a beta of 0.92. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The firm’s 50 day moving average is $115.19 and its 200 day moving average is $84.73. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 488.26%. The business had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. During the same period in the previous year, the business earned $1.72 EPS. Halozyme Therapeutics’s revenue was up 39.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 8.32 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.